Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1, PHASE2

מצבים רפואיים

Recurrent Glioblastoma, IDH-Wildtype · Recurrent MGMT-Methylated Glioblastoma

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States

    Contact: Study coordinator (Alyx B. Porter Umphrey) · porter.alyx@mayo.edu · 507-538-7623
    Contact: Principal Investigator (Alyx B. Porter Umphrey)
  • City of Hope Comprehensive Cancer Center, Duarte, California, United States

    Contact: Study coordinator (Site Public Contact) · becomingapatient@coh.org · 800-826-4673
    Contact: Principal Investigator (Jana L. Portnow)
  • UC San Diego Moores Cancer Center, La Jolla, California, United States

    Contact: Study coordinator (Site Public Contact) · cancercto@ucsd.edu · 858-822-5354
    Contact: Principal Investigator (David E. Piccioni)
  • Keck Medicine of USC Koreatown, Los Angeles, California, United States

  • Los Angeles General Medical Center, Los Angeles, California, United States

  • USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

  • University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

    Contact: Study coordinator (Site Public Contact) · 916-734-3089
    Contact: Principal Investigator (Orwa Aboud)
  • UCHealth University of Colorado Hospital, Aurora, Colorado, United States

    Contact: Study coordinator (Site Public Contact) · 720-848-0650
    Contact: Principal Investigator (Denise M. Damek)
  • UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States

    Contact: Study coordinator (Site Public Contact) · 305-243-2647
    Contact: Principal Investigator (Macarena I. De La Fuente)
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States

    Contact: Study coordinator (Site Public Contact) · 305-243-2647
    Contact: Principal Investigator (Macarena I. De La Fuente)
  • Mayo Clinic in Florida, Jacksonville, Florida, United States

    Contact: Study coordinator (Site Public Contact) · 855-776-0015
    Contact: Principal Investigator (Sani H. Kizilbash)
  • University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States

    Contact: Study coordinator (Site Public Contact) · 305-243-2647
    Contact: Principal Investigator (Macarena I. De La Fuente)
  • Moffitt Cancer Center, Tampa, Florida, United States

    Contact: Study coordinator (Site Public Contact) · ClinicalTrials@moffitt.org · 800-679-0775
    Contact: Principal Investigator (Patrick T. Grogan)
  • Emory University Hospital Midtown, Atlanta, Georgia, United States

    Contact: Study coordinator (Site Public Contact) · 888-946-7447
    Contact: Principal Investigator (Kimberly Hoang)
  • Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

    Contact: Study coordinator (Site Public Contact) · 404-778-1868
    Contact: Principal Investigator (Kimberly Hoang)
  • University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · cancerclinicaltrials@bsd.uchicago.edu · 773-702-8222
    Contact: Principal Investigator (Steven J. Chmura)
  • University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States

    Contact: Study coordinator (Site Public Contact) · cancerclinicaltrials@bsd.uchicago.edu · 773-702-8222
    Contact: Principal Investigator (Steven J. Chmura)
  • University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States

    Contact: Study coordinator (Site Public Contact) · 859-257-3379
    Contact: Principal Investigator (John L. Villano)
  • Mayo Clinic in Rochester, Rochester, Minnesota, United States

    Contact: Study coordinator (Site Public Contact) · 855-776-0015
    Contact: Principal Investigator (Sani H. Kizilbash)
  • Saint Barnabas Medical Center, Livingston, New Jersey, United States

    Contact: Study coordinator (Site Public Contact) · joanne.loeb@rwjbh.org · 973-322-2934
    Contact: Principal Investigator (Vincent Yeung)
  • Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

    Contact: Study coordinator (Site Public Contact) · 732-235-7356
    Contact: Principal Investigator (Vincent Yeung)
  • Rutgers New Jersey Medical School, Newark, New Jersey, United States

    Contact: Study coordinator (Site Public Contact) · 732-235-7356
    Contact: Principal Investigator (Vincent Yeung)
  • Roswell Park Cancer Institute, Buffalo, New York, United States

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States

    Contact: Study coordinator (Site Public Contact) · CancerTrials@nyulangone.org
    Contact: Principal Investigator (Jose R. McFaline Figueroa)
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States

  • Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

    Contact: Study coordinator (Site Public Contact) · 336-713-6771
    Contact: Principal Investigator (Roy E. Strowd)
  • University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · cancer@uchealth.com · 513-584-7698
    Contact: Principal Investigator (Lalanthica V. Yogendran)
  • Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jamesline@osumc.edu · 800-293-5066
    Contact: Principal Investigator (Pierre Giglio)
  • University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · cancer@uchealth.com · 513-584-7698
    Contact: Principal Investigator (Lalanthica V. Yogendran)
  • University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

    Contact: Study coordinator (Site Public Contact) · ou-clinical-trials@ouhsc.edu · 405-271-8777
    Contact: Principal Investigator (James D. Battiste)
  • University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

    Contact: Study coordinator (Site Public Contact) · 412-647-8073
    Contact: Principal Investigator (Megan Mantica)
  • Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

  • University of Virginia Cancer Center, Charlottesville, Virginia, United States

  • VCU Massey Comprehensive Cancer Center, Richmond, Virginia, United States

    Contact: Study coordinator (Site Public Contact) · CTOclinops@vcu.edu · 804-628-6430
    Contact: Principal Investigator (Mariza Daras)
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin, United States

    Contact: Study coordinator (Site Public Contact) · clinicaltrials@cancer.wisc.edu · 800-622-8922
    Contact: Principal Investigator (Ankush Bhatia)
  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States

    Contact: Study coordinator (Site Public Contact) · clinicaltrials@cancer.wisc.edu · 800-622-8922
    Contact: Principal Investigator (Ankush Bhatia)
מובילי המחקר
  • Frances E Chow

    Principal Investigator

    City of Hope Comprehensive Cancer Center LAO